Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Konstantinos Arnaoutakis

Concepts (127)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Lung Neoplasms
6
2024
605
1.790
Why?
Carcinoma, Non-Small-Cell Lung
4
2024
154
1.670
Why?
Protein Kinase Inhibitors
2
2024
206
1.260
Why?
Piperidines
1
2024
98
0.900
Why?
Hematology
3
2022
24
0.870
Why?
Medical Oncology
3
2022
95
0.690
Why?
Pyrazoles
2
2024
114
0.680
Why?
Neoplasms
4
2018
1249
0.660
Why?
Adenocarcinoma, Clear Cell
1
2017
34
0.580
Why?
Bone Marrow
2
2016
363
0.560
Why?
Leukemia, Promyelocytic, Acute
1
2016
11
0.540
Why?
Anemia, Aplastic
1
2016
12
0.540
Why?
Pancytopenia
1
2016
37
0.520
Why?
Communication
2
2016
246
0.490
Why?
Physician-Patient Relations
1
2016
141
0.480
Why?
Protein-Tyrosine Kinases
1
2015
95
0.480
Why?
Proto-Oncogene Proteins
1
2015
149
0.470
Why?
Bone Marrow Neoplasms
1
2014
13
0.470
Why?
Seminoma
1
2013
8
0.460
Why?
Pyridines
1
2015
131
0.450
Why?
Biopsy, Fine-Needle
1
2014
103
0.450
Why?
Hodgkin Disease
1
2014
44
0.450
Why?
Paralysis
1
2013
9
0.450
Why?
Spinal Cord Neoplasms
1
2013
14
0.440
Why?
Testicular Neoplasms
1
2013
64
0.440
Why?
Lymphoma, Large B-Cell, Diffuse
1
2013
106
0.400
Why?
Aged
12
2024
9405
0.380
Why?
Antineoplastic Agents
4
2024
1186
0.360
Why?
Bronchial Neoplasms
1
2009
5
0.350
Why?
Lymphoma, B-Cell, Marginal Zone
1
2009
23
0.340
Why?
Fellowships and Scholarships
2
2022
111
0.330
Why?
Humans
22
2024
50208
0.310
Why?
Female
12
2024
26635
0.280
Why?
Middle Aged
8
2024
12206
0.280
Why?
Carbazoles
1
2024
16
0.240
Why?
Lactams
1
2024
22
0.240
Why?
Aminopyridines
1
2024
15
0.240
Why?
Sulfones
1
2024
24
0.240
Why?
Treatment Outcome
5
2024
5155
0.240
Why?
Neoplasm Metastasis
2
2016
236
0.230
Why?
Tomography, X-Ray Computed
3
2014
1161
0.220
Why?
Pyrimidines
1
2024
193
0.210
Why?
Antineoplastic Combined Chemotherapy Protocols
4
2016
990
0.210
Why?
Radiography
2
2013
491
0.200
Why?
Male
9
2024
25399
0.200
Why?
Retrospective Studies
4
2024
6134
0.180
Why?
Adult
6
2024
13324
0.170
Why?
Integrative Medicine
1
2018
9
0.150
Why?
Patients
1
2018
49
0.150
Why?
Quality Improvement
2
2016
209
0.150
Why?
Terminal Care
1
2018
46
0.150
Why?
Keratins
1
2017
27
0.150
Why?
Doxorubicin
2
2017
239
0.150
Why?
DNA, Neoplasm
1
2018
147
0.150
Why?
Nanotubes
1
2017
27
0.150
Why?
Qualitative Research
2
2018
336
0.150
Why?
Oncogene Proteins, Fusion
1
2017
58
0.140
Why?
Silver
1
2017
47
0.140
Why?
Drug Carriers
1
2017
71
0.140
Why?
Neoplasm, Residual
1
2018
165
0.140
Why?
Attitude to Health
1
2018
191
0.140
Why?
Mastication
1
2016
5
0.140
Why?
Constipation
1
2016
35
0.140
Why?
Education, Medical
1
2018
112
0.140
Why?
Chemotherapy, Adjuvant
2
2013
120
0.130
Why?
Pyrroles
1
2016
69
0.130
Why?
Gold
1
2017
136
0.130
Why?
Learning
1
2018
159
0.130
Why?
Quality Assurance, Health Care
1
2016
149
0.130
Why?
Antibodies, Monoclonal
2
2017
460
0.130
Why?
Salvage Therapy
2
2013
139
0.130
Why?
Carcinoma, Renal Cell
1
2016
105
0.130
Why?
Quality of Health Care
1
2016
187
0.120
Why?
Computer Simulation
1
2016
280
0.120
Why?
Membrane Proteins
1
2017
353
0.120
Why?
Kidney Neoplasms
1
2016
176
0.120
Why?
Factor VIII
1
2014
23
0.120
Why?
Purpura, Thrombotic Thrombocytopenic
1
2014
15
0.120
Why?
ADAM Proteins
1
2014
20
0.120
Why?
Plasma Exchange
1
2014
23
0.120
Why?
Immunohistochemistry
1
2017
978
0.120
Why?
Reed-Sternberg Cells
1
2014
2
0.120
Why?
HIV Seronegativity
1
2014
3
0.120
Why?
Orchiectomy
1
2013
41
0.120
Why?
Scrotum
1
2013
30
0.110
Why?
Bronchoscopy
1
2014
70
0.110
Why?
Indoles
1
2016
278
0.110
Why?
Pain
1
2016
381
0.110
Why?
Fatal Outcome
1
2013
195
0.110
Why?
Diagnosis, Differential
1
2016
1043
0.100
Why?
Positron-Emission Tomography
1
2014
294
0.100
Why?
Biopsy
1
2014
590
0.100
Why?
Analgesics, Opioid
1
2016
557
0.090
Why?
Aged, 80 and over
3
2014
3154
0.090
Why?
Neoplasm Recurrence, Local
1
2013
613
0.090
Why?
Nausea
1
2008
50
0.080
Why?
Morpholines
1
2008
70
0.080
Why?
Vomiting
1
2008
75
0.080
Why?
Survival Analysis
1
2009
666
0.080
Why?
Immunotherapy
1
2009
240
0.070
Why?
Neoplasm Staging
1
2009
738
0.070
Why?
Patient Satisfaction
2
2016
275
0.060
Why?
Prognosis
1
2009
1954
0.060
Why?
Accreditation
1
2022
60
0.050
Why?
Education, Medical, Graduate
1
2022
205
0.040
Why?
Coated Materials, Biocompatible
1
2017
34
0.040
Why?
Spectrum Analysis, Raman
1
2017
58
0.040
Why?
Genotype
1
2018
534
0.030
Why?
Molecular Targeted Therapy
1
2017
121
0.030
Why?
Young Adult
2
2016
3981
0.030
Why?
Cell Survival
1
2017
602
0.030
Why?
Autoantibodies
1
2014
116
0.030
Why?
Cell Line, Tumor
1
2017
1416
0.030
Why?
Immunosuppressive Agents
1
2014
222
0.030
Why?
Combined Modality Therapy
1
2014
636
0.030
Why?
Carcinoma, Small Cell
1
2010
25
0.020
Why?
SEER Program
1
2010
92
0.020
Why?
Antiemetics
1
2008
32
0.020
Why?
Cyclophosphamide
1
2008
166
0.020
Why?
Drug Therapy, Combination
1
2008
381
0.020
Why?
Dexamethasone
1
2008
430
0.020
Why?
United States
1
2016
4874
0.020
Why?
Adolescent
1
2016
6390
0.020
Why?
Dose-Response Relationship, Drug
1
2008
1378
0.020
Why?
Prospective Studies
1
2008
2379
0.010
Why?
Time Factors
1
2008
2922
0.010
Why?
Breast Neoplasms
1
2008
1179
0.010
Why?
Arnaoutakis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description